George Stouffer, MD
Cardiovascular Disease · Chapel Hill, NDNPI 1003994286
Payments from drug & device makers
What this record shows
9 manufacturers reported payments, led by Abbott at 43.7% of the total. Reporting peaked in 2019 at $1,211 and has fallen 77.7% since, to $270 in 2025.
Across 29 payments — averaging $125.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Amgen$1K
- Medtronic$418
- Novo Nordisk$216
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$131
- Recor Medical Inc$50
- plus $49 from 3 others
Across 25 payments — averaging $10,366 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$204K
- Recor Medical Inc$56K
What the payments were for
- Consulting fees$2,05056%
- Food & beverage$1,59644%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $1,593 |
| Amgen | 2 | $1,190 |
| Medtronic | 10 | $418 |
| Novo Nordisk | 2 | $216 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $131 |
| Recor Medical Inc | 2 | $50 |
| Abiomed | 1 | $22 |
| Philips North America LLC | 1 | $14 |
| Terumo Medical Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$1,100
- HeartMate Touch$950
- OPTIS$260
- Optis Coronary Imaging System$250
- SYMPLICITY G3$153
- LifeVest$131
- Ozempic$114
How this compares
$3,646 in reported general payments places this provider in the 55th percentile of 35 cardiovascular disease providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 39 | $47,951 |
| EliquisApixaban | 18 | $22,700 |
| FarxigaDapagliflozin Propanediol | 16 | $13,371 |
| XareltoRivaroxaban | 11 | $12,356 |
| NexletolBempedoic Acid | 12 | $4,812 |
| Prasugrel Hcl | 40 | $2,407 |
| Atorvastatin Calcium | 81 | $894 |
| ClopidogrelClopidogrel Bisulfate | 67 | $885 |
| Metoprolol Succinate | 66 | $654 |
| Verapamil ErVerapamil Hcl | 14 | $645 |
| Rosuvastatin Calcium | 50 | $474 |
| Losartan Potassium | 57 | $409 |
| Valsartan | 11 | $405 |
| Ezetimibe | 35 | $381 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 23 | $380 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Chapel Hill
- Noah ChelliahGrand Forks$115K
- Beng Loong Isaac TeaMinot$42K
- Hussain BasrawalaGrand Forks$40K
- Thomas HaldisFargo$37K
- Matthew GlogozaFargo$36K
- Mikhail KirnusGrand Forks$16K
- Timothy PansegrauBismarck$16K
- Jason GoFargo$15K
- Rabeea AboufakherGrand Forks$14K
- Padmaraj DuvvuriFargo$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.